TapewireFind a company

person · Reporting owner

Sanders Corazon (Corsee) D.

Disclosed activity across 5 companies

Tapewire entity
21675
SEC CIK
0001796536

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
BeOne Medicines Ltd.ONC · Entity 2168DirectorMay 22, 2026May 27, 2026
Calidi Biotherapeutics, Inc.CLDI · Entity 8408DirectorAugust 17, 2026August 19, 2026
Legend Biotech CorpLEGN · Entity 4033DirectorSeptember 29, 2026October 02, 2026
Molecular Templates, Inc.MTEM · Entity 85987DirectorSeptember 27, 2024September 30, 2024
Ultragenyx Pharmaceutical Inc.RARE · Entity 4337DirectorJune 15, 2026June 15, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BeOne Medicines Ltd.

Report date May 22, 2026 · Filed May 27, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
American Depositary SharesSEC Table I · non-derivativeDirect0 Reported balance After 2026-05-22 transaction · row 2 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 2 · 2026-05-22 · Sale · Disposed 212 · Balance 0

F1: Each American Depositary Share represents 13 Ordinary Shares.

F2: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events.

Ordinary SharesSEC Table I · non-derivativeDirect54,470 Reported balance Holding disclosure · report date 2026-05-22 · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · Balance 54,470

Filing footnotes · ownership attribution and instrument terms

F1: Each American Depositary Share represents 13 Ordinary Shares.

F2: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events.

Calidi Biotherapeutics, Inc.

Report date August 17, 2026 · Filed August 19, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Non-Qualified Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.36 · Expires 2036-08-17Direct6,000 Reported balance After 2026-08-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-08-17 · Grant · Acquired 6,000 · Balance 6,000

F1: On August 17, 2026, the Reporting Person was issued a non-qualified stock option to purchase 6,000 shares of common stock (the "Options") at an exercise price of $1.36 per share (equal to the closing price on the grant date, August 17, 2026) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan.

F2: Does not include the stock options previously granted to the Reporting Person.

Filing footnotes · ownership attribution and instrument terms

F1: On August 17, 2026, the Reporting Person was issued a non-qualified stock option to purchase 6,000 shares of common stock (the "Options") at an exercise price of $1.36 per share (equal to the closing price on the grant date, August 17, 2026) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan.

F2: Does not include the stock options previously granted to the Reporting Person.

Legend Biotech Corp

Report date September 29, 2026 · Filed October 02, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Ordinary SharesSEC Table I · non-derivativeDirect52,731 Reported balance After 2026-09-29 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2026-09-29 · Sale · Disposed 27,370 · Balance 52,731

F1: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.

F2: The price reported in Column 4 is a weighted average price. The prices sold ranged from $9.445 to $9.48 per ordinary share. The reporting person will provide the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.

Filing footnotes · ownership attribution and instrument terms

F1: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.

F2: The price reported in Column 4 is a weighted average price. The prices sold ranged from $9.445 to $9.48 per ordinary share. The reporting person will provide the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.

Molecular Templates, Inc.

Report date September 27, 2024 · Filed September 30, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.41 · Expires 2034-09-27Direct1,000 Reported balance After 2024-09-27 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2024-09-27 · Grant · Acquired 1,000 · Balance 1,000

F1: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of September 27, 2024.

Filing footnotes · ownership attribution and instrument terms

F1: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of September 27, 2024.

Ultragenyx Pharmaceutical Inc.

Report date June 15, 2026 · Filed June 15, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect21,095 Reported balance After 2026-06-15 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2026-06-15 · Sale · Disposed 2,000 · Balance 21,095

F1: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Filing footnotes · ownership attribution and instrument terms

F1: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
September 29, 2026 Filed Oct 2, 2026 00:04 UTC Legend Biotech Corp LEGN · Entity 4033 SaleOrdinary Shares 27,370 $9.46 $258,920.20
Disclosure

SEC source: 0001796536-26-000010 · form4-10012026_081003.xml · nonDerivative · entry 1

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,731

F1 · security: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.

F2 · price: The price reported in Column 4 is a weighted average price. The prices sold ranged from $9.445 to $9.48 per ordinary share. The reporting person will provide the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
September 24, 2026 Filed Sep 28, 2026 20:10 UTC Legend Biotech Corp LEGN · Entity 4033 GrantOrdinary Shares 20,986 $0.00 $0.00
Disclosure

SEC source: 0001796536-26-000009 · form4-09282026_040901.xml · nonDerivative · entry 1

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,101

F1 · security: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.

F2 · shares: Represents restricted share units (the "RSUs"). Each RSU represents a contingent right to receive one ordinary share of the Issuer upon settlement. 1/3 of the RSUs will vest on December 20, 2027, with the remainder of the RSUs vesting in 12 equal quarterly installments beginning on March 20, 2028, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Read SEC document
August 17, 2026 Filed Aug 19, 2026 23:00 UTC Calidi Biotherapeutics, Inc. CLDI · Entity 8408 GrantNon-Qualified Stock Options (right to buy) · Derivative 6,000 $0.00 Strike: $1.36 $0.00
Disclosure

SEC source: 0001493152-26-039285 · ownership.xml · derivative · entry 1

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,000

Underlying: Common Stock · 6,000 shares

Expires 2036-08-17

F1 · security: On August 17, 2026, the Reporting Person was issued a non-qualified stock option to purchase 6,000 shares of common stock (the "Options") at an exercise price of $1.36 per share (equal to the closing price on the grant date, August 17, 2026) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan.

F1 · derivative.exercise_date: On August 17, 2026, the Reporting Person was issued a non-qualified stock option to purchase 6,000 shares of common stock (the "Options") at an exercise price of $1.36 per share (equal to the closing price on the grant date, August 17, 2026) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan.

F2 · balance_after: Does not include the stock options previously granted to the Reporting Person.

Read SEC document
June 15, 2026 Filed Jun 15, 2026 22:50 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 SaleCommon Stock 2,000 $25.05 $50,100.00
Disclosure

SEC source: 0001796536-26-000007 · ownership.xml · nonDerivative · entry 1

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,095

F1 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Read SEC document
May 22, 2026 Filed May 27, 2026 21:26 UTC BeOne Medicines Ltd. ONC · Entity 2168 SaleAmerican Depositary Shares 212 $309.59 $65,633.00
Disclosure

SEC source: 0001796536-26-000005 · wk-form4_1779917164.xml · nonDerivative · entry 2

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events.

Read SEC document
May 14, 2026 Filed May 18, 2026 22:38 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 GrantStock Option (Right to Buy) · Derivative 14,058 $0.00 Strike: $25.80 $0.00
Disclosure

SEC source: 0001796536-26-000004 · ownership.xml · derivative · entry 2

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,058

Underlying: Common Stock · 14,058 shares

Expires 2036-05-14

F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.

Read SEC document
May 14, 2026 Filed May 18, 2026 22:38 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 GrantCommon Stock 7,751 $0.00 $0.00
Disclosure

SEC source: 0001796536-26-000004 · ownership.xml · nonDerivative · entry 1

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,095

F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.

Read SEC document
November 26, 2025 Filed Dec 1, 2025 21:57 UTC BeOne Medicines Ltd. ONC · Entity 2168 Exercise / conversionShare Option (Right to Buy) · Derivative 34,151 $0.00 Strike: $12.23 $0.00
Disclosure

SEC source: 0001796536-25-000005 · wk-form4_1764626273.xml · derivative · entry 5

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 34,151 shares

Expires 2034-06-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares.

F5 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors (the "Board") or otherwise ceases to serve as a director, unless the Board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended.

Read SEC document
November 26, 2025 Filed Dec 1, 2025 21:57 UTC BeOne Medicines Ltd. ONC · Entity 2168 SaleAmerican Depositary Shares 804 $342.47 $275,349.10
Disclosure

SEC source: 0001796536-25-000005 · wk-form4_1764626273.xml · nonDerivative · entry 4

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $342.42 to $342.675, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Read SEC document
November 26, 2025 Filed Dec 1, 2025 21:57 UTC BeOne Medicines Ltd. ONC · Entity 2168 SaleAmerican Depositary Shares 1,823 $340.20 $620,185.33
Disclosure

SEC source: 0001796536-25-000005 · wk-form4_1764626273.xml · nonDerivative · entry 3

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 804

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $340.04 to $340.68, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Read SEC document
November 26, 2025 Filed Dec 1, 2025 21:57 UTC BeOne Medicines Ltd. ONC · Entity 2168 Exercise / conversionAmerican Depositary Shares 2,627 $159.03 $417,771.81
Disclosure

SEC source: 0001796536-25-000005 · wk-form4_1764626273.xml · nonDerivative · entry 2

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,627

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

Read SEC document
September 05, 2025 Filed Sep 9, 2025 21:31 UTC BeOne Medicines Ltd. ONC · Entity 2168 Exercise / conversionShare Option (Right to Buy) · Derivative 34,645 $0.00 Strike: $11.98 $0.00
Disclosure

SEC source: 0001651308-25-000139 · wk-form4_1757453510.xml · derivative · entry 4

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 34,645 shares

Expires 2032-06-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares.

F3 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors (the "Board") or otherwise ceases to serve as a director, unless the Board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended.

Read SEC document
September 05, 2025 Filed Sep 9, 2025 21:31 UTC BeOne Medicines Ltd. ONC · Entity 2168 SaleAmerican Depositary Shares 2,665 $337.00 $898,105.00
Disclosure

SEC source: 0001651308-25-000139 · wk-form4_1757453510.xml · nonDerivative · entry 3

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

Read SEC document
September 05, 2025 Filed Sep 9, 2025 21:31 UTC BeOne Medicines Ltd. ONC · Entity 2168 Exercise / conversionAmerican Depositary Shares 2,665 $155.68 $414,887.20
Disclosure

SEC source: 0001651308-25-000139 · wk-form4_1757453510.xml · nonDerivative · entry 2

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,665

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

Read SEC document
June 20, 2025 Filed Jun 23, 2025 17:50 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 SaleCommon Stock 2,405 $37.39 $89,922.95
Disclosure

SEC source: 0000950170-25-088878 · ownership.xml · nonDerivative · entry 1

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,344

Read SEC document
May 21, 2025 Filed May 22, 2025 23:42 UTC BeOne Medicines Ltd. BGNE · Entity 2168 GrantShare Option (Right to Buy) · Derivative 22,750 $0.00 Strike: $18.19 $0.00
Disclosure

SEC source: 0001651308-25-000086 · wk-form4_1747957367.xml · derivative · entry 2

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,750

Underlying: Ordinary Shares · 22,750 shares

Expires 2035-05-20

F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares.

F3 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended.

Read SEC document
May 21, 2025 Filed May 22, 2025 23:42 UTC BeOne Medicines Ltd. BGNE · Entity 2168 GrantOrdinary Shares 10,985 $0.00 $0.00
Disclosure

SEC source: 0001651308-25-000086 · wk-form4_1747957367.xml · nonDerivative · entry 1

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,226

F1 · security: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The restricted share units were granted under the Company's Independent Director Compensation Policy, as amended.

Read SEC document
May 15, 2025 Filed May 19, 2025 22:33 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 GrantStock Option (Right to Buy) · Derivative 10,787 $0.00 Strike: $34.84 $0.00
Disclosure

SEC source: 0000950170-25-074666 · ownership.xml · derivative · entry 2

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,787

Underlying: Common Stock · 10,787 shares

Expires 2035-05-15

F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 15, 2026.

Read SEC document
May 15, 2025 Filed May 19, 2025 22:33 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 GrantCommon Stock 5,740 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-074666 · ownership.xml · nonDerivative · entry 1

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,749

F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 15, 2026.

Read SEC document
September 27, 2024 Filed Sep 30, 2024 17:35 UTC Molecular Templates, Inc. MTEM · Entity 85987 GrantStock Option (right to buy) · Derivative 1,000 $0.00 Strike: $1.41 $0.00
Disclosure

SEC source: 0000950170-24-110454 · ownership.xml · derivative · entry 1

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,000

Underlying: Common Stock · 1,000 shares

Expires 2034-09-27

F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of September 27, 2024.

Read SEC document
July 02, 2024 Filed Jul 3, 2024 18:07 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 SaleCommon Stock 584 $40.98 $23,932.32
Disclosure

SEC source: 0000950170-24-081302 · ownership.xml · nonDerivative · entry 1

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,009

Read SEC document
June 18, 2024 Filed Jun 20, 2024 18:22 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 GrantStock Option (Right to Buy) · Derivative 9,900 $0.00 Strike: $37.42 $0.00
Disclosure

SEC source: 0000950170-24-075485 · ownership.xml · derivative · entry 2

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,900

Underlying: Common Stock · 9,900 shares

Expires 2034-06-18

F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 18, 2025.

Read SEC document
June 18, 2024 Filed Jun 20, 2024 18:22 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 GrantCommon Stock 5,345 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-075485 · ownership.xml · nonDerivative · entry 1

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,593

F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 18, 2025.

Read SEC document
June 10, 2024 Filed Jun 10, 2024 23:58 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 SaleCommon Stock 1,737 $41.10 $71,390.70
Disclosure

SEC source: 0000950170-24-071548 · ownership.xml · nonDerivative · entry 1

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,248

F1 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Read SEC document
June 05, 2024 Filed Jun 7, 2024 20:55 UTC BeOne Medicines Ltd. BGNE · Entity 2168 GrantShare Option (Right to Buy) · Derivative 34,151 $0.00 Strike: $12.23 $0.00
Disclosure

SEC source: 0001651308-24-000057 · wk-form4_1717793720.xml · derivative · entry 2

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,151

Underlying: Ordinary Shares · 34,151 shares

Expires 2034-06-04

F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares.

F2 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares.

F3 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended.

Read SEC document
June 05, 2024 Filed Jun 7, 2024 20:55 UTC BeOne Medicines Ltd. BGNE · Entity 2168 GrantOrdinary Shares 16,341 $0.00 $0.00
Disclosure

SEC source: 0001651308-24-000057 · wk-form4_1717793720.xml · nonDerivative · entry 1

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,241

F1 · security: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The restricted share units were granted under the Company's Independent Director Compensation Policy, as amended.

Read SEC document
October 27, 2023 Filed Oct 31, 2023 18:46 UTC Molecular Templates, Inc. MTEM · Entity 85987 GrantStock Option (right to buy) · Derivative 1,000 $0.00 Strike: $6.06 $0.00
Disclosure

SEC source: 0001171843-23-006569 · ownership.xml · derivative · entry 1

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,000

Underlying: Common Stock · 1,000 shares

Expires 2033-10-27

F1 · date: The figures reflected herein have been adjusted to take into account a 1 for 15 reverse split of the Company's common stock that was effected on August 11, 2023.

F2 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of October 27, 2023.

Read SEC document
June 30, 2023 Filed Jun 30, 2023 18:34 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 SaleCommon Stock 585 $46.76 $27,354.60
Disclosure

SEC source: 0001209191-23-040269 · doc4.xml · nonDerivative · entry 1

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,985

F1 · shares: The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023.

Read SEC document
June 23, 2023 Filed Jun 27, 2023 21:21 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleAmerican Depositary Shares 478 $182.65 $87,307.42
Disclosure

SEC source: 0001651308-23-000101 · wf-form4_168790086732122.xml · nonDerivative · entry 3

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $182.34 to $183.05, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Read SEC document
June 23, 2023 Filed Jun 27, 2023 21:21 UTC BeOne Medicines Ltd. BGNE · Entity 2168 SaleAmerican Depositary Shares 100 $180.74 $18,074.00
Disclosure

SEC source: 0001651308-23-000101 · wf-form4_168790086732122.xml · nonDerivative · entry 2

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 478

F1 · security: Each American Depositary Share represents 13 Ordinary Shares.

F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2023.

Read SEC document
June 15, 2023 Filed Jun 20, 2023 23:08 UTC BeOne Medicines Ltd. BGNE · Entity 2168 GrantShare Option (Right to Buy) · Derivative 26,975 $0.00 Strike: $16.41 $0.00
Disclosure

SEC source: 0001651308-23-000099 · wf-form4_168730246724090.xml · derivative · entry 2

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,975

Underlying: Ordinary Shares · 26,975 shares

Expires 2033-06-14

F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares.

F2 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares.

F3 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended.

Read SEC document
June 15, 2023 Filed Jun 20, 2023 23:08 UTC BeOne Medicines Ltd. BGNE · Entity 2168 GrantOrdinary Shares 12,922 $0.00 $0.00
Disclosure

SEC source: 0001651308-23-000099 · wf-form4_168730246724090.xml · nonDerivative · entry 1

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,414

F1 · security: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The restricted share units were granted under the Company's Independent Director Compensation Policy, as amended.

Read SEC document
June 08, 2023 Filed Jun 9, 2023 18:31 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 SaleCommon Stock 1,485 $51.65 $76,700.25
Disclosure

SEC source: 0001209191-23-035690 · doc4.xml · nonDerivative · entry 2

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,570

F2 · shares: The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023.

Read SEC document
June 07, 2023 Filed Jun 9, 2023 18:31 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 GrantStock Option (Right to Buy) · Derivative 7,110 $0.00 Strike: $51.82 $0.00
Disclosure

SEC source: 0001209191-23-035690 · doc4.xml · derivative · entry 3

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,110

Underlying: Common Stock · 7,110 shares

Expires 2033-06-07

F3 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 7, 2024.

Read SEC document
June 07, 2023 Filed Jun 9, 2023 18:31 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 GrantCommon Stock 3,860 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-035690 · doc4.xml · nonDerivative · entry 1

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,055

F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 7, 2024.

Read SEC document
June 24, 2022 Filed Jun 29, 2022 19:48 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 GrantStock Option (Right to Buy) · Derivative 6,245 $0.00 Strike: $60.57 $0.00
Disclosure

SEC source: 0001209191-22-039770 · doc4.xml · derivative · entry 2

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,245

Underlying: Common Stock · 6,245 shares

Expires 2032-06-24

F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2023.

Read SEC document
June 24, 2022 Filed Jun 29, 2022 19:48 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 GrantCommon Stock 3,300 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-039770 · doc4.xml · nonDerivative · entry 1

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,195

F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2023.

Read SEC document
June 22, 2022 Filed Jun 24, 2022 21:37 UTC BeOne Medicines Ltd. BGNE · Entity 2168 GrantShare Option (Right to Buy) · Derivative 34,645 $0.00 Strike: $11.98 $0.00
Disclosure

SEC source: 0001651308-22-000105 · wf-form4_165610664484850.xml · derivative · entry 2

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,645

Underlying: Ordinary Shares · 34,645 shares

Expires 2032-06-21

F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares.

F2 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares.

F3 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended.

Read SEC document
June 22, 2022 Filed Jun 24, 2022 21:37 UTC BeOne Medicines Ltd. BGNE · Entity 2168 GrantOrdinary Shares 16,692 $0.00 $0.00
Disclosure

SEC source: 0001651308-22-000105 · wf-form4_165610664484850.xml · nonDerivative · entry 1

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,492

F1 · security: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The restricted share unites were granted under the Company's Independent Director Compensation Policy, as amended.

Read SEC document
June 03, 2022 Filed Jun 6, 2022 16:15 UTC Molecular Templates, Inc. MTEM · Entity 85987 GrantStock Option (right to buy) · Derivative 15,000 $0.00 Strike: $0.97 $0.00
Disclosure

SEC source: 0000899243-22-021187 · doc4.xml · derivative · entry 1

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2032-06-02

F1 · derivative.exercise_date: 100% of the total number of shares subject to the option shall vest on June 3, 2023.

Read SEC document
June 29, 2021 Filed Jun 30, 2021 23:58 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 GrantStock Option (Right to Buy) · Derivative 7,255 $0.00 Strike: $96.29 $0.00
Disclosure

SEC source: 0001209191-21-044165 · doc4.xml · derivative · entry 2

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,255

Underlying: Common Stock · 7,255 shares

Expires 2031-06-29

F2 · derivative.exercise_date: The option shall vest with respect to 1/36th of the shares monthly such that the option shall fully vest on the third anniversary of the grant date.

Read SEC document
June 29, 2021 Filed Jun 30, 2021 23:58 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 GrantCommon Stock 3,895 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-044165 · doc4.xml · nonDerivative · entry 1

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,895

F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/3rd of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the third anniversary of the grant date.

Read SEC document
June 16, 2021 Filed Jun 21, 2021 20:35 UTC BeOne Medicines Ltd. BGNE · Entity 2168 GrantShare Option (Right to Buy) · Derivative 17,498 $0.00 Strike: $26.53 $0.00
Disclosure

SEC source: 0001651308-21-000120 · wf-form4_162430771425098.xml · derivative · entry 2

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,498

Underlying: Ordinary Shares · 17,498 shares

Expires 2031-06-15

F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares.

F2 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares.

F3 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events.

Read SEC document
June 16, 2021 Filed Jun 21, 2021 20:35 UTC BeOne Medicines Ltd. BGNE · Entity 2168 GrantOrdinary Shares 7,800 $0.00 $0.00
Disclosure

SEC source: 0001651308-21-000120 · wf-form4_162430771425098.xml · nonDerivative · entry 1

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,800

F1 · security: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events.

Read SEC document
June 03, 2021 Filed Jun 4, 2021 16:30 UTC Molecular Templates, Inc. MTEM · Entity 85987 GrantStock Option (right to buy) · Derivative 15,000 $0.00 Strike: $8.98 $0.00
Disclosure

SEC source: 0000899243-21-022044 · doc4.xml · derivative · entry 1

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2031-06-03

F1 · derivative.exercise_date: 100% of the total number of shares subject to the option shall vest on June 3, 2022.

Read SEC document
August 24, 2020 Filed Aug 26, 2020 20:51 UTC BeOne Medicines Ltd. BGNE · Entity 2168 GrantShare Option (Right to Buy) · Derivative 27,482 $0.00 Strike: $18.26 $0.00
Disclosure

SEC source: 0001651308-20-000141 · wf-form4_159847508819916.xml · derivative · entry 1

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,482

Underlying: Ordinary Shares · 27,482 shares

Expires 2030-08-23

F1 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares.

F1 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares.

F2 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended.

Read SEC document
May 28, 2020 Filed Jun 1, 2020 17:05 UTC Molecular Templates, Inc. MTEM · Entity 85987 GrantStock Option (right to buy) · Derivative 15,000 $0.00 Strike: $15.43 $0.00
Disclosure

SEC source: 0000899243-20-014734 · doc4.xml · derivative · entry 1

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2030-05-28

F1 · derivative.exercise_date: 100% of the total number of shares subject to the option shall vest on May 28, 2021

Read SEC document
December 19, 2019 Filed Dec 20, 2019 08:05 UTC Molecular Templates, Inc. MTEM · Entity 85987 GrantStock Option (right to buy) · Derivative 25,000 $0.00 Strike: $12.69 $0.00
Disclosure

SEC source: 0000899243-19-029722 · doc4.xml · derivative · entry 1

Sanders Corazon (Corsee) D. · CIK 0001796536 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2029-12-19

F1 · derivative.exercise_date: 50% of the total number of shares subject to the option shall vest on December 19, 2020 and the remaining 50% shall vest on December 19, 2021, subject to the reporting person's continuous service with Molecular Templates, Inc.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.